Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
On May24, 2017, Aerie Pharmaceuticals, Inc. (the Company) issued
a press release announcing the topline safety and efficacy
results from the Companys Phase 3 Mercury 2 registration trial
for its product candidate, RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%. A copy of the press release is
furnished as Exhibit 99.1 hereto and is hereby incorporated by
reference into this Item7.01.
On or after May24, 2017, representatives of the Company may
present to various investors the information about the topline
results of Mercury 2 described in the slides attached to this
report as Exhibit 99.2 hereto, which is hereby incorporated by
reference into this Item7.01.
The information in this Item7.01 (including Exhibits99.1 and
99.2) is being furnished, not filed, to Regulation FD.
Accordingly, the information in this Item7.01 will not be
incorporated by reference into any registration statement filed
by the Company under the Securities Act of 1933, as amended,
unless specifically identified therein as being incorporated
therein by reference. The furnishing of the information in this
Item7.01 is not intended to, and does not, constitute a
determination or admission by the Company that this information
is material or complete, or that investors should consider this
information before making an investment decision with respect to
any security of the Company.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits relating to Item 7.01 shall be deemed to
be furnished, and not filed:
| 99.1 | Press Release dated May24, 2017. | |
| 99.2 |
RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Mercury 2 Phase 3 Topline Results. |
About Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. Its product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Rhopressa is a once-daily eye drop and a triple-action netarsudil ophthalmic solution. The active ingredient in Rhopressa acts through the inhibition of both Rho Kinase (ROCK) and norepinephrine transporter (NET). Roclatan is a once-daily, quadruple-action product candidate and is a fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with glaucoma. The Company is engaged in conducting Phase III clinical trials for Rhopressa and Roclatan. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Recent Trading Information
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) closed its last trading session down -0.30 at 40.50 with 207,624 shares trading hands.